J. Köster

Safety of Telmisartan in Patients with Arterial Hypertension

U. Heemann, M. Michel, R. Schäfers, 2004, Drug safety.

The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial

G. Navis, D. de Zeeuw, J. Reid, 2005, Journal of hypertension.

Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo

D. de Zeeuw, J. Reid, A. Manolis, 2004, Journal of hypertension.

Differential diagnosis of unpleasant sensations in the legs: prevalence of restless legs syndrome in a primary care population.

K. Stiasny‐Kolster, T. Wetter, J. Köster, 2010, Sleep medicine.

Pramipexole in Routine Clinical Practice

H. Reichmann, P. Kraus, J. Köster, 2003, CNS drugs.

Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in Parkinson's disease

M. Nöthen, T. Klockgether, S. Paus, 2004, Movement disorders : official journal of the Movement Disorder Society.

Changing dopamine agonist treatment in Parkinson's disease: experiences with switching to pramipexole.

H. Reichmann, P. Odin, P. Kraus, 2006, Journal of neural transmission. Supplementum.

Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease

Thomas Klockgether, Ullrich Wüllner, T. Klockgether, 2003, Movement disorders : official journal of the Movement Disorder Society.

Long‐term efficacy and safety of pramipexole in advanced Parkinson's disease: Results from a European multicenter trial

W. Oertel, L. Provinciali, J. C. Möller, 2005, Movement disorders : official journal of the Movement Disorder Society.